Oxford Biomedica plc (FRA:OXOA)

Market Cap	1.16B +128.3%
Revenue (ttm)	176.41M +55.4%
Net Income	-43.24M
EPS	-0.42
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	349
Open	9.55
Previous Close	9.70
Day's Range	9.45 - 9.55
52-Week Range	2.44 - 10.90
Beta	n/a
RSI	59.24
Earnings Date	Apr 9, 2026

About Oxford Biomedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and de...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 900
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: OXOA

Financial Performance

In 2024, Oxford Biomedica's revenue was 128.80 million, an increase of 43.84% compared to the previous year's 89.54 million. Losses were -43.19 million, -72.58% less than in 2023.

Financial numbers in GBP